| 货号 | 15225-250mg |
| 描述 | SL 01 is a prodrug of gemcitabine (Item No. 11690), the nucleoside analog used intravenously to treat various cancers that was designed for improved oral bioavailability.1 SL 01 can inhibit the growth of human non-small cell lung cancer NCI-H460 cells, colon cancer HCT116 cells, and breast cancer MCF-7 cells (IC50s = 0.78, 0.92, and 0.64 μM, respectively), inducing apoptosis.2,3 In nude mice bearing NCI-H460, HCT116, or MCF-7 cancer cell xenografts, SL 01 at 10-50 μM/kg has been shown to delay tumor growth.2,3 |
| 别名 | NSC 251810; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Zhao, C.,Li, Y.,Wang, R., et al. Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. Cancer Chemotherapy and Pharmacology 71(6), 1541-1550 (2013). 2.Zhao, C.,Yue, B.,Liu, H., et al. SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine. Toxicology and Applied Pharmacology 262(3), 293-300 (2012). 3.Li, Y.Y.,Qin, Y.Z.,Wang, R.Q., et al. SL-01, an oral derivative of gemcitabine, inhibited human breast cancer growth through induction of apoptosis. Biochemical and Biophysical Research Communications 438(2), 402-409 (2013). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 331.8 |
| 分子式 | C18H18ClNO3 |
| CAS号 | 26049-94-5 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |